Shots:
- Boston Scientific has entered into a definitive agreement to acquire Penumbra, expanding its cardiovascular portfolio
- As per the deal, Boston Scientific will acquire Penumbra for $374/share, with Penumbra stockholders having the option to receive either $374 in cash or 3.8721 shares of Boston Scientific’s common stock, representing the enterprise value of ~$14.5B; closing expected in 2026
- Acquisition will add Penumbra’s mechanical thrombectomy solutions, incl. Lightning Bolt & Lightning Flash CAVT systems for arterial, venous & pulmonary clot removal, plus a minimally invasive embolization platform to control bleeding & vessel closure
Ref: PRnewswire | Image: Penumbra|Press Release
Related News: Boston Scientific to Acquire Nalu Medical for ~$533M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
